ID   SK-MEL-103
AC   CVCL_6069
SY   SK-Mel-103; SKMEL-103; SkMel103; SKMEL103
DR   cancercelllines; CVCL_6069
DR   ChEMBL-Cells; CHEMBL4483143
DR   ChEMBL-Targets; CHEMBL4483267
DR   Cosmic; 685207
DR   Cosmic; 1054850
DR   Cosmic; 1122258
DR   Cosmic; 1507613
DR   Cosmic; 1669161
DR   GEO; GSM555127
DR   GEO; GSM555180
DR   GEO; GSM784512
DR   GEO; GSM3039513
DR   Lonza; 1337
DR   Millipore; SCC439
DR   Progenetix; CVCL_6069
DR   PubChem_Cell_line; CVCL_6069
DR   Wikidata; Q54953761
RX   PubMed=7747814;
RX   PubMed=17308088;
RX   PubMed=18505964;
RX   PubMed=21343389;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=7747814).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): Millipore=SCC439
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 13
ST   D18S51: 13,15
ST   D21S11: 31.2
ST   D3S1358: 14
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 13,15
ST   FGA: 20
ST   Penta D: 12
ST   Penta E: 10,12
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=7747814; PMCID=PMC1869278;
RA   Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I.,
RA   Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H.,
RA   Cordon-Cardo C., Kamb A.;
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=18505964; DOI=10.1093/jnci/djn157; PMCID=PMC4410798;
RA   Freedberg D.E., Rigas S.H., Russak J.E., Gai W.-M., Kaplow M.E.,
RA   Osman I., Turner F., Randerson-Moor J.A., Houghton A.N., Busam K.J.,
RA   Bishop D.T., Bastian B.C., Newton-Bishop J.A., Polsky D.;
RT   "Frequent p16-independent inactivation of p14ARF in human melanoma.";
RL   J. Natl. Cancer Inst. 100:784-795(2008).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//